Epix Medical raises $23 million:
This article was originally published in Clinica
Executive Summary
Epix Medical, a developer of MRI contrast agents, has raised around $23 million in a follow-on stock offering. The company, which is based in Cambridge, Massachusetts, plans to use the proceeds for R&D and funding for clinical trials, in particular for the MS-325, an injectable contrast agent for multiple vascular imaging indications.